PULMONX CORP
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs applyAbout LUNG
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Find out what a historical investment in PULMONX CORP would be worth today using our LUNG stock calculator.
$119.97M
-
0.00%
0
$3.05
$2.94
$0.00
$9.37
$2.83
Ready to start your investing journey with Stake?
Open an accountLUNG FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in LUNG
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in LUNG
on Stake
Buy LUNG from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of LUNG from only US$10 with fractional shares
